The global brain implants market size was valued at USD 3.01 billion in 2016. Rising incidence of neurological disorders such as Parkinson’s, Alzheimer’s, epilepsy, depression, and essential tremors is one of the key trends contributing to the growth of the market.
As per the statistics of WHO, in February 2016, about 50 million people were suffering from epilepsy. According to data shared by Parkinson’s News Today, each year, around 60,000 Americans are affected with Parkinson’s disease. In addition, growing geriatric population is stimulating market growth as aged people are more prone to neurological diseases. Furthermore, availability of technologically advanced and cost-efficient technology for the treatment is expected to augment the market over the forecast period. For instance, researchers developed a method to stimulate brain tissues electrically without opening the skull.
Furthermore, the market is estimated to witness lucrative growth in the coming years owing to increasing number of research activities leading to technological breakthroughs. These include self-charging implants and memory chips, which are anticipated to provide key players with growth opportunities in future. Moreover, smart neural chips facilitate wireless transmission of brain signals to fingers and hands with approximately 95% accuracy and this is projected to augment the demand for neural chips during the forecast period.
On the basis of product, the market is segmented into deep brain stimulator (DBS), spinal cord stimulator (SCS), and vagus nerve stimulator (VNS). The deep brain stimulator segment commanded the largest market share in 2016 due to its use in various applications. The product is anticipated to maintain its dominance throughout the forecast horizon due to rising incidence of Parkinson’s disease. Growing adoption of DBS for the treatment of various neurological disorders, including obsessive compulsive disorder (OCD), dystonia, essential tremor, epilepsy, and Alzheimer’s disease, is a key factor driving the growth of this segment.
Vagus nerve stimulator is poised to be the fastest growing segment during the forecast period due to growing incidence of epilepsy. Cases of epilepsy are rising due to brain injuries, stroke, and lifestyle. As per the findings of CDC, around 1.2% of the U.S. population in 2015 had active epilepsy.
On the basis of application, the global brain implants market has been segmented into chronic pain, epilepsy, Parkinson’s disease, depression, essential tremor, and Alzheimer’s disease. Stimulators are mainly used in cases where chronic neck or back pain has not been relieved despite surgery or other treatments. According to data published by Pain Doctor in 2017, every year, there are about 14,000 patients globally who use spinal cord implants. With increasing chronic pain due to conditions such as lumbar and cervical radiculitis, failed back surgery, complex regional pain syndrome, and neuropathy, the demand for stimulators is rising. Therefore, chronic pain accounted for the largest share in 2016.
Parkinson’s disease is likely to register the highest CAGR over the forecast period owing to decline in smoking rate and coffee consumption, particularly in developed countries, which may increase the incidence of the disease.
North America dominated the market in 2016. High investment in R&D activities, domicile of a large number of prominent market players, and frequent product approvals are supplementing the growth of the regional market.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to rising awareness among the population regarding availability of brain implants and growing healthcare expenditure in emerging economies such as China and India.
Boston Scientific; Medtronic; St. Jude Medical; Nevro Corporation; NeuroPace Inc.; and NDI Medical LLC are key players in the market. These players contribute majority of the market revenue. They are involved in adopting extensive growth strategies such as entering into alliances, increasing differentiation and diversification of product portfolio, and broadening marketing and distribution channels in an attempt to increase the outreach of their products.
For instance, in April 2015, Boston Scientific entered into an alliance with Brainlab AG to expand its DBS therapy product portfolio. This collaboration also led to intensive distribution of Brainlab’s surgical planning portfolio with Vercise DBS System in certain countries. Moreover, development of low cost products is leading to high competition among existing players.
Report Attribute |
Details |
Market size value in 2020 |
USD 4.7 billion |
Revenue forecast in 2025 |
USD 8.29 billion |
Growth Rate |
CAGR of 11.9% from 2017 to 2025 |
Base year for estimation |
2016 |
Historical data |
2014 - 2015 |
Forecast period |
2017 - 2025 |
Quantitative units |
Revenue in USD million and CAGR from 2017 to 2025 |
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors and trends |
Segments covered |
Product, application, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
Country scope |
U.S., Canada, U.K., Germany, France, Japan, China, Brazil, Mexico, South Africa |
Key companies profiled |
Boston Scientific; Medtronic; Abbott (St. Jude Medical); Nevro Corporation; NeuroPace Inc.; NDI Medical LLC. |
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth and provides an analysis on latest industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research, Inc. has segmented the brain implants market report on the basis of product, application and region:
Product Outlook (Revenue, USD Million, 2014 - 2025)
Deep brain stimulation
Spinal cord stimulation
Vagus nerve stimulation
Application Outlook (Revenue, USD Million, 2014 - 2025)
Chronic pain
Epilepsy
Parkinson’s disease
Depression
Essential tremor
Alzheimer’s disease
Regional Outlook (Revenue, USD Million, 2014 - 2025)
North America
U.S.
Canada
Europe
Germany
U.K.
Asia Pacific
Japan
China
Latin America
Brazil
Mexico
Middle East and Africa (MEA)
South Africa
b. The global brain implants market size was estimated at USD 4.2 billion in 2019 and is expected to reach USD 4.7 billion in 2020.
b. The global brain implants market is expected to grow at a compound annual growth rate of 11.9% from 2017 to 2025 to reach USD 8.2 billion by 2025.
b. North America dominated the brain implants market with a share of 43.36% in 2019. This is attributable to high investment in R&D activities, domicile of a large number of prominent market players, and frequent product approvals.
b. Some of the key players operating in the brain implants market include Boston Scientific; Medtronic; Abbott (St. Jude Medical); Nevro Corporation; NeuroPace Inc.; and NDI Medical LLC.
b. Key factors that are driving the brain implants market growth include rising incidence of neurological disorders such as Parkinson’s, Alzheimer’s, epilepsy, depression, and essential tremors.
This report has a service guarantee. We stand by our report quality.
We are in compliance with GDPR & CCPR norms. All interactions are confidential.
Design an exclusive study to serve your research needs.
Get your queries resolved from an industry expert.
"The quality of research they have done for us has been excellent..."
With Covid-19 infections rising globally, the apprehension regarding a shortage of essential life-saving devices and other essential medical supplies in order to prevent the spread of this pandemic and provide optimum care to the infected also widens. In addition, till a pharmacological treatment is developed, ventilators act as a vital treatment preference for the COVID-19 patients, who may require critical care. Moreover, there is an urgent need for a rapid acceleration in the manufacturing process for a wide range of test-kits (antibody tests, self-administered, and others). The report will account for Covid19 as a key market contributor.